Abstract: The present invention provides vitamin E succinate (VES)-stabilized compositions, methods for the preparation thereof and methods useful for the in vivo delivery of substantially water insoluble and optionally chemically unstable pharmacologically active agents (such as docetaxel).
Abstract: The present invention is directed to novel capsules containing active materials and methods for making capsules with enhanced performance and stability. The capsules are well suited for use in personal care applications, laundry products and perfume and fragrance products.
Abstract: Novel biaromatic compounds having the general formula (I): and cosmetic/pharmaceutical compositions comprised thereof are useful in human or veterinary medicine (in dermatology and also in the fields of cardiovascular diseases, of immune diseases and/or of diseases related to the metabolism of lipids) or, alternatively, in cosmetic compositions.
Abstract: Powder treated with a powder treating agent comprising organohydrogenpolysiloxane, characterized in that the organohydrogenpolysiloxane has a weight average molecular weight of from 300 to 100,000, at least one SiH bond per molecule, and at least one selected from (R23SiO1/2) unit and (SiO2) unit, wherein R1 is selected from the group consisting of a hydrogen atom, and alkyl, fluorinated alkyl, aryl and aralkyl groups each having 1 to 30 carbon atoms.
Abstract: The present invention provides formulations which greatly improve the physical and chemical stability of pesticides such as insect growth regulators, in liquid feeds, and liquid feed supplements. The present invention prevents or reduces stratification in liquid feeds and liquid feed supplements.
Type:
Application
Filed:
May 11, 2007
Publication date:
September 6, 2007
Applicant:
Wellmark International Central Life Sciences
Inventors:
Dennis Murphy, Jeanne Witte, Kim Yang, Joe McDaniel
Abstract: The present invention is directed to a biocidal composition comprising a blend of one or more pyrithione compounds, and one or more pyrrole compounds of Formula I wherein said biocidal composition is copper free or low copper content.
Type:
Application
Filed:
March 3, 2006
Publication date:
September 6, 2007
Inventors:
Craig Waldron, Robert Martin, Gareth Williams, Tina Williams
Abstract: A medical device, such as a guide wire, an embolization device, or a guide shaft for a micro catheter, comprises a solid and/or non-expandable core member made from e.g. metal, such as tantalum, and an outer surface layer, which is formed by electrospun nanofibers. The outer surface layer may incorporate a pharmaceutically active substance, such as a nitric oxide (NO) donor for release in the vascular or neurovascular system of a living being. The NO donor may be incorporated in a polymer, such as a polymeric linear poly(ethylenimine) diazeniumdiolate.
Type:
Application
Filed:
October 14, 2004
Publication date:
September 6, 2007
Inventors:
Erik Andersen, Daniel Smith, Darrell Reneker
Abstract: The present invention provides a bioapplicable material (or composition) or film-forming material (or composition), which is free from a risk of an infection by a pathogenic organism or a transmission of a causative factor, has a high safety. The material (or composition) comprises a collagen-like synthetic polypeptide having at least an amino acid sequence represented by the formula -Pro-Y-Gly- (wherein Y represents Pro or Hyp). The polypeptide may show positive Cotton effect at a wavelength in range of 220 to 230 nm and negative Cotton effect at a wavelength in range of 195 to 205 nm in a circular dichroism spectrum. At least part of the polypeptide may be capable of forming a triple helical structure. The polypeptide may be degradable with a collagenase.
Abstract: Provided herein are a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.
Abstract: Medical devices configured for implantation or insertion into a subject, which contain one or more particle-containing region that comprises electrically aligned, elongated particles within a matrix. Also described are methods for forming the same.
Abstract: The invention relates to medical devices coated with zein. The medical device may include further a therapeutic agent in contact with zein. Zein allows the therapeutic agent to be retained on the device during delivery and also controls the elution rate of the therapeutic agent following implantation. The invention further relates to methods of delivering a therapeutic agent on said medical devices as well as their use especially in the form of stents for prevention of restenosis.
Type:
Application
Filed:
January 5, 2007
Publication date:
September 6, 2007
Applicant:
MED Institute, Inc.
Inventors:
Patrick Ruane, Christy Casterline, Amy Vibbert, Waleska Perez-Segarra
Abstract: The present invention provides an implantable medical device comprising a bioactive agent and poly(alkyl cyanoacrylate) polymer. In one embodiment of the invention, the bioactive agent is a water-soluble material, such as an antisense agent.
Type:
Application
Filed:
January 19, 2007
Publication date:
September 6, 2007
Applicant:
MED Institute, Inc
Inventors:
Patrick Ruane, Jeff Little, Andrew Isch
Abstract: The present invention is a more durable expanded material that enables thinner wall thicknesses and a more flexible reinforcement suitable for stenting. The present invention is especially useful in the construction of grafts, stents, and stent-grafts which are used, for example, in repairing or replacing blood vessels that are narrowed or occluded by disease, aneurismal blood vessels, or other medical treatments. The inventive material and configurations allow expansion or contraction in size or adjustment in size in an incremental manner so that the optimum size, shape, and fit with other objects can be obtained. The present invention is also optionally capable of more accurately delivering one or more active ingredients such as drugs over longer periods of time. The present invention optionally includes surface modifications and additives that increase the surface adhesion of active ingredients, coatings, or combinations thereof.
Abstract: There is provided a functional composition or food comprising whey protein, an antibody derived from milk or the other antibody; and a whey protein food comprising whey protein and glucide, cocoa powder, powdery an unsolidifiable and insoluble substance, green tea, aloe, turmeric, pumpkin, red grape juice, tomato, cranberry, raspberry, blueberry or strawberry powder.
Abstract: The invention provides, in one aspect, a method of administering a product comprising a cacao solids-containing, cocoa powder or extract containing cocoa polyphenols to improve endothelial function. The sugar-free compositions and methods of using them exhibit synergistically improved cardiovascular benefits compared to other compositions. Preferred sugar-free chocolate products and cocoa beverages are also disclosed.
Abstract: Antimicrobial medical devices are prepared with a complexed antimicrobial agent which enhances the adherence of the antimicrobial agent to the medical device.
Abstract: Method for producing hydrophobic polymers, wherein a hydrophobic polymer is selected; a set of organisms is selected from among cells and/or cell products; aggregates are formed by working said cells and/or cell products in said polymers resulting in the formation of a so-called polymer-bio aggregate, wherein there is performed a new function of the thus polymer product. This invention further relates to the use of a so-called P.B.A. obtained therewith in specific applications.
Type:
Application
Filed:
March 5, 2007
Publication date:
September 6, 2007
Applicant:
RESILUX
Inventors:
William Dierickx, Dirk De Cuyper, Yvan Dierickx, Dirk Mertens, Johan Mertens, Lynda Beladjal
Abstract: Compositions and methods are provided that comprise improved means to achieve and maintain a targeted level of copper status in persons in order to treat and prevent copper associated diseases.
Type:
Application
Filed:
May 7, 2007
Publication date:
September 6, 2007
Inventors:
Steve KANZER, George Brewer, Nicholas Stergis, John Althaus, Charles Bisgaier
Abstract: The present invention is directed to a mucoadhesive delivery system for the local or systemic administration of a pharmaceutical agent. The delivery system of the invention effectively and facilely enables transport of the pharmaceutical agent through mucosal membranes and into the vasculattire of the mucosa. The delivery system includes an at least partially water soluble bioadhesive layer and an at least partially water soluble backing layer. Incorporated within either or both of these layers are the pharmaceutical agent and a mucosal penetration enhancing agent. The mucosal penetration enhancing agent displays localized tissue irritation properties. The mucoadhesive delivery system may be in the form of a gel, film, disc or patch. It may be applied to any mucosal membrane of a patient including but not limited to those of the buccal and nasal cavities, throat, eye, vagina, alimentary tract and peritoneum.
Abstract: A method of ameliorating neurogenic tremor in mammals, which comprises topically administering to a mammal, which has been diagnosed with a neurogenic tremor, an effective amount of a topical anesthetic.
Abstract: The present invention includes compositions and methods for delivering one or more active agents in vivo by contacting a target organ or tissue with a microbubble encapsulated active agent comprising a neutrally charged lipid microbubble loaded with cationic liposomes comprising one or more active agents and selectively releasing the active agents at the target by exposing the microbubble at the target with ultrasound, wherein the active agents remain protected in the microbubble until selectively release at the target.
Abstract: Methods are disclosed for genetically counseling a person based on one or more polymorphisms in his or her genes that sensitize him or her to toxic agents. Methods are also disclosed for genetically screening a group of individuals and/or a human population, based on, for example, ethnicity, race, religion or geographic region, to identify individuals with such polymorphisms for counseling. The methods can be used to counsel a person who has not been genetically tested for polymorphisms but who might have increased risk for sensitivity to toxic agents due to his or her membership in a particular group and/or population. The methods use correlations between genotypes of polymorphic alleles in a panel of cell lines and sensitivity of the cell lines to toxic agents. As examples, the methods are used to identify genotypes of allelic forms of the genes TP53, OGG1, ERCC2, XRCC1, and NOS3 that increase sensitivity or resistance of cells to toxic agents.
Abstract: Tocopherol-modified therapeutic drug compounds; emulsion, microemulsion, and micelle formulations that include the compounds; methods for making the compounds and formulations; methods for administering the compounds and formulations; and methods for treating conditions using the compounds and formulations.
Abstract: A composition and method used to reduce the symptoms associated with breast engorgement, galactorrhea, and other associated disorders. More specifically, this invention is related to a cabbage extract combined with a base cream having liposomes that are applied to each breast of a patient suffering from a symptom of breast engorgement, galactorrhea, and other associated disorders.
Type:
Application
Filed:
February 9, 2007
Publication date:
September 6, 2007
Inventors:
J.A. Villarreal, Noe Lira, Thelma Lira, Yolanda Villarreal
Abstract: The present invention has disclosed a use of N-acetyl-D-glucosamine in the preparation of a medicament for treating tumors and metastatic diseases. N-acetyl-D-glucosamine is able to regulate cellular membrane, constitute a stable structural component of cellular membrane, participate metabolism process of tumor cells, and stop energy supply to cause the death of tumor cells. As a drug for adjustment therapy, it showed significant effects in the laboratory researches, animal tests and human body trials.
Type:
Application
Filed:
September 17, 2003
Publication date:
September 6, 2007
Applicant:
Beijing Sino-Hong Kong Dafu Science & Technology of Biowave Co., Ltd.
Abstract: An appetite suppression device includes an ingestible, expandable membrane in surrounding an expandable reactant material. The membrane is contained in a capsule. A reactant enabling mechanism is integrated with the expandable membrane to enable the reactant after ingestion of the membrane by a subject. enabling mechanism may comprise a pore in one portion of the membrane. Alternatively, the enabling mechanism may be a separation of the membrane into two portions, each having materials which, when combined, react to expand the membrane.
Abstract: The present invention is directed to dosage forms that can be used in therapeutic methods involving the oral co-administration of a combination of at least two drugs, one of which impairs gastrointestinal absorption and one of which does not. The dosage forms are designed so that the drug impairing absorption is not released into the gastrointestinal tract of a patient until after the drugs that do not impair absorption have been released and substantially absorbed. The invention may be used in treatment of migraine using a combination of triptans and NSAIDs or in the treatment of pain using a combination of NSAIDs and opioid analgesics.
Abstract: The present invention is directed to liquid or semi-solid pharmaceutical formulations of pharmacologically active agents of Formula I that are estrogen receptor modulators, and pharmaceutical compositions and preparative processes thereof.
Type:
Application
Filed:
March 5, 2007
Publication date:
September 6, 2007
Applicant:
Wyeth
Inventors:
Mahesh K. Krishnan, Mohamed Ghorab, Rolland W. Carson, Shamim Hasan, Arwinder S. Nagi
Abstract: The present invention is directed to pharmaceutical formulations of a monohydrate crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof.
Type:
Application
Filed:
March 5, 2007
Publication date:
September 6, 2007
Applicant:
Wyeth
Inventors:
Mahesh K. Krishnan, Mohamed Ghorab, Rolland W. Carson, Shamim Hasan, Arwinder S. Nagi
Abstract: The present invention relates to a novel controlled release dosage form that releases therapeutic amounts of a sedative or hypnotic agent rapidly after administration and maintains therapeutic levels for about eight hours after administration.
Abstract: The present invention provides a multi-release oral drug delivery system that initiates drug release following an initial drug-free release interval, after administration to a subject, and a second drug-free release period before release of another dose of drug. The system has (1) inner compartments enclosed within a semipermeable membrane, and (2) a drug coating on the exterior of the semipermeable membrane surrounded by a microporous membrane, which microporous membrane is permeable to fluid and drug. The drug coating is released after the initial drug-free release interval. An inner compartment drug is released after a second drug-free release interval provided by a drug-free inner compartment.
Abstract: The present invention concerns a rapidly disintegrating taste-masked tablet having both hardness and non-friability properties comprising at least one active principle selected from the group of mineral salts, vitamins and mixtures thereof, the active principle being coated by a sweetening agent wherein the weight ratio of the active principle to the sweetening agent is from 0.2 to 3, and starch and microcrystalline cellulose in a weight ratio of starch to microcrystalline cellulose from about 0.76 to 0.85, and at least one free flow aid. It also concerns a method for the preparation of such a tablet.
Abstract: One embodiment of a chewable pain relief composition includes acetaminophen, present in a therapeutically-effective amount, ibuprofen, present in a therapeutically-effective amount, and a chewable binding agent, present in an amount effective to facilitate breakdown of the composition during chewing thereof.
Abstract: Formulations for controlled delivery of oral transmucosal medications are provided. The formulations are characterized as hydrogel-forming or eroding-types which are bioadhesive and provide for controlled and sustained release of the medication such that enhanced bioavailability and efficacy is provided.
Type:
Application
Filed:
January 5, 2007
Publication date:
September 6, 2007
Applicant:
AcelRx Pharmaceuticals, Inc.
Inventors:
Stelios Tzannis, Pamela Palmer, Thomas Schreck, Larry Hamel, Andrew Poutiatine
Abstract: A method of treating patients suffering from renal failure and concomitant cardiovascular disease with a low dose of the cardiac glycoside known as digoxin, and novel dosage forms to accomplish the method and to perform other uses.
Abstract: The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.
Type:
Application
Filed:
August 29, 2005
Publication date:
September 6, 2007
Inventors:
Christopher Murphy, Jonathan McAnulty, Gordon Mitchell, Francis Golder
Abstract: The present disclosure relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is subjected to a liquid-solid phase separation to cause the active agent to form small spherical particles that are substantially amorphous or non-crystalline and are injectable through fine bore needles at high concentrations. The particles exhibit the pharmacokinetic and pharmacodynamnic properties of the active agent. The disclosure has special application for higher molecular weight proteins such as antibodies.
Abstract: The apparatus, methods and compositions of the present invention are of use for the production of emulsion-based microparticles containing a biological or chemical agent. The apparatus and methods of the present invention provide for a low-shear, non-turbulent, production of emulsion-based microparticles that provides a narrow, reproducible, particle size distribution, capable of use with both large and small volumes that is conveniently scaled up while providing predictable emulsion properties. The methods include production of emulsion-based microparticles containing a biological or chemical agent which, when suspended in a diluent, are syringable through a needle without clumping of the microparticles or clogging of the needle.
Abstract: Disclosed herein is a method of making a film, the method comprising depositing a first layer polyelectrolyte on a surface of a substrate to form a first layer; and depositing a second layer polyelectrolyte on the first layer polyelectrolyte to form a second layer. The first layer polyelectrolyte, the second layer polyelectrolyte, or both, is deposited on the substrate in the presence of a polymeric precipitant; and the first layer polyelectrolyte and the second layer polyelectrolyte have net charges of opposite polarity. Also disclosed are methods of improving bioactive molecule retention during fabrication of a polyelectrolyte multilayer film.
Abstract: Injectable drug laden microspheres are obtained from unsaturated functionalized polyhydric alcohol ester of polyester by a method comprising dissolving the unsaturated functionalized ester in a hydrophobic organic solvent, dissolving drug and/or biologically active agent in water, admixing the two solutions to form water-in-oil emulsion, forming an aqueous solution of stabilizer, admixing the water-in-oil emulsion and the stabilizer solution to form water-in-oil-in-water emulsion, and evaporating the organic solvent.
Abstract: The invention concerns a galenic system with prolonged/controlled release of the medicinal and/or nutritional active principle, for oral administration. The aim is to provide a system enabling to obtain with one single tolerable and acceptable dose of active principle, efficient therapeutic protection over 24 hours (increasing the bioabsorption time without affecting bioavailability).
Abstract: Honey is treated thermally At 100-160° and the obtained solution is settled. Then the solution is mixed with adsorbent and again settled, further it is filtered. The obtained filtrate represents a soluble medicinal means pH of which is 3-4. To receive a dry powder the soluble filtrate is mixed with a pharmaceutically acceptable auxiliary means and the obtained mixture is dried. The soluble medicinal means and the dry powder are used as a bactericidal, antiviral, immunostimulating, anti-blastoma and regenerative means. An ointment contains the above mentioned soluble medicinal means, propolis, oil of St-John's wort, beeswax and water. The said ointment is used for treatment of wounds of skin and soft tissues, burns, purulent processes and trophic ulcers.
Abstract: A kit for colonic cleansing includes a phosphate salt laxative, a flavorant, and an oral rehydration mixture. The flavorant includes aspartame and a citrate, and the oral rehydration mixture includes sodium and a glucose containing saccharide. The kit may be used for a colonic cleansing procedure by combining the phosphate salt laxative and the flavorant to provide a flavored laxative liquid, orally administering to a subject the flavored laxative liquid, and orally administering to the subject an oral rehydration liquid.
Abstract: The present invention relates to molybdenum carbonyl complexes useful for inhibiting tumor necrosis factor (TNF) production and for treating inflammatory diseases.
Type:
Application
Filed:
December 20, 2006
Publication date:
September 6, 2007
Applicant:
Alfama - Investigacao e Desenvolvimento De Productos Farmaceuticos Lda
Inventors:
Werner Haas, Carlos Romao, Sandra Rodrigues, Joao Seixas, Ana Pina, Beatriz Royo, Ana Fernandes, Isabel Goncalves
Abstract: Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.
Abstract: An object of the present invention is to provide a Mallotus philippinensis extract containing readily water soluble rottlerin. A further object of the present invention is to improve convenience at production steps in a method for producing such an extract, by avoiding the staining of filters and/or pipes during extraction and filtration to reduce washing costs, or by facilitating the introduction of freeze drying and so on. When a dye extract is extracted with water and alcohol from a Mallotus philippinensis plant body, the addition of a base component drastically improves the water solubility of the Mallotus philippinensis extract. This improves extraction rates of rottlerin, facilitates washing in the production and the pulverization of the extract, and also improves the water solubility of the obtained extract.
Abstract: The invention relates to a method for improving the sleep behaviors of a human comprising the administration of a sensory regimen which comprises: a. the administration of a first sensory experience comprising topically applying to the skin or hair of the human a cleansing product containing an effective amount of a sensory fragrance; and b. after step (a) the administration of a second sensory experience comprising administering an effective amount of a sensory fragrance. The sensory fragrance used in step (a) and the sensory fragrance used in step (b) can be the same or different and is capable of reducing alpha activity.
Abstract: The present invention relates to a composition including a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatological disorder, the composition being in liquid or light gel form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal. The invention also relates to a method of treating a tar-responsive dermatological disorder by topically applying the composition to skin of a mammal, preferably a human, that is involved with the disorder.
Type:
Application
Filed:
February 28, 2007
Publication date:
September 6, 2007
Applicant:
TriStrata, Inc.
Inventors:
Ruey J. Yu, Eugene J. Van Scott, Yaling Lee